
price close busi novemb
biomed devic servic
bottom line except quarter highest us growth rate sinc
total revenu growth nearli y/i support strong growth
sensor volum offset price pressur hardwar increas global
adopt cgm on-going uptak demonstr
strong oper leverag track first year
profroma profit look forward continu drive patient awar
expect robust new patient addit persist ye investor
sentiment continu impact abbott impend approval/launch next
gener libr look event bear say rais
concern regard stabil lt price margin note overhang
like persist fda approv hand better idea full clinic
util accuraci cgm statu regardless continu believ market
larg enough support multipl player global finger-stick test coalesc around
player manufactur focu product pipelin profession
use hospit gestat posit compani strong line-up fulli
equip lower cost technolog said expect share volatil continu base
competit product approv suggest investor use opportun build
add posit sum remain bullish near- long-term product
pipelin grow opportun deliv upsid expect
beyond buy
result revenu y/i vs cg/consensu estim
us sale grew y/i benefit grow market
awar accept cgm effort lower up-front barrier adopt
includ shift pharmaci channel ou revenu also strong
y/i manag note recent launch canada show
earli success uk grow significantli despit limit reimburs gm
y/i due headwind increas invest scale
infrastructur drive capac expans continu shift mix
toward pharmaci channel
capac constraint invest growth clear effort lower barrier
adopt shift patient pharmaci channel extrem success
explos growth demand system patient clinician
much manag note demand impact constraint suppli
custom support continu expect compani invest heavili meet
increas demand end compani track doubl capac
plan doubl capac importantli leverag
aforement infrastructur invest support launch
initi support growth beyond control launch expect
late broad launch earli schedul major design
lock compani prep pivot secondli key partnership tndm
control-iq podd horizon companion inpen etc continu track posit
lastli highlight ww cgm penetr remain earli inning
compani work secur access new market includ japan
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guidanc chang estim
lift revenu guidanc growth
 growth gross margin guidanc lower
rang non-gaap om guidanc increas
non-gaap adjust ebitda margin guidanc lift
made follow chang estim
figur summari estim revis
buy unchang target price novemb
biomed devic servic
resultsactualcg estbeat/miss beat/miss consensusbeat/miss total revenu total gross oper net result categoryactualcg estbeat/missbeat/miss prior yeary/i growthnet sale except ep newold newold newold product
high-growth med-tech comp group current trade mean ev/sal multipl
estim revenu sum increas price target base
ev/sal multipl appli revenu estim
price target assum cash debt share
outstand
figur matrix discount rate impli share price target
buy unchang target price novemb
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price novemb
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price novemb
biomed devic servic
